Aim. The aim of this study was to evaluate the diagnostic utility of natriuretic peptides of type A and B as noninvasive markers in the diagnosis and treatment of congenital and valvular heart disease.
INTRODUCTION
Valvular heart disease is any disease process involving one or more of the valves of the heart (the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right). Valve problems may be congenital (inborn) or acquired (due to another cause later in life).
Heart valve dysplasia is an error in the development of any of the heart valves, and a common cause of congenital heart defects in humans as well as animals; tetralogy of Fallot is a congenital heart defect with four abnormalities, one of which is stenosis of the pulmonary valve. Ebstein's anomaly is an abnormality of the tricuspid valve. Valvular heart disease is commonly caused by damage to the heart muscle as a result of rheumatic fever or a congenital abnormality. Valvular heart problems can be corrected surgically, by direct repair of the valve, replacement of the damaged valve with an artificial valve, or by a non-surgical technique called balloon valvuloplasty. Patients with valvular heart disease are also at risk for bacterial endocarditis. Cardiac auscultation and various non-invasive and invasive cardiac tests are necessary to establish a firm diagnosis which is the basis for rational treatment of the underlying disorder. Two-dimensional and Doppler echocardiography is particularly useful in this regard 1 . This study provides evidence for the natriuretic peptides (NT-proBNP-N-terminal pro-brain natriuretic peptide and atrial natriuretic peptide -proANP) as non-invasive cardiac markers in establishing diagnosis, management and treatment of congenital and valvular heart diseases.
MATERIALS AND METHODS

Patients
Eighty two samples of both blood serum or blood plasma from patients (36 males, mean age of 46 years, range 22-75 years and 46 females, mean age of 45 years, range 22-79 years) with various types of valvular heart diseases were collected for investigation of serum NT-proBNP levels and plasma mid-regional proANP levels. Consecutive ambulatory patients were previously examined in a specialized Cardiology Department. Clinically relevant indices (hypertension, history of acute myocardial infarction, treatment by angiotensin converting enzyme (ACE) inhibitors and angiotensin antagonists, beta blockers and diuretics, left ventricular ejection fraction, systolic and diastolic pressure and kidney function expressed as S-creatinine levels) were investigated. Echocardiography was used to determine the degree of severity of the heart diseases.
Patient characteristic are listed in Table 1 .
Methods
Blood samples were collected by venipuncture into tubes (Sarstedt, Vacutainer) containing EDTA as an anticoagulant. Immediately after the collection were samples transported in laboratory and after centrifugation (4000 g at 4°C and 10 min) the aliquots of serum and plasma were frozen immediately and kept at -20°C until proANP and NT-proBNP were analyzed. Serum levels of NT-proBNP were measured using a commercially available electrochemiluminescence sandwich immunoassay (ECLIA, Roche, Germany) on Elecsys System 2010. Plasma mid-re- 
Statistical analysis
Differences between the medians for reference values of both natriuretic peptides and the medians in patients with valvular heart diseases were tested for statistical significance by the Wilcoxon Signed rank test. P < 0.05 was considered as statistically significant difference.
RESULTS
Blood serum and plasma concentrations of both natriuretic peptides were significantly elevated in patients with congenital and valvular heart disease as compared with reference values. Both peptides showed positive correlation with age and gender. A summary of the results is shown in Table 2 .
The non significant differences in the group of males over 60 years for NT-proBNP, and in females over 56 years for N-MID-proANP may have been due to large variability and range of results (males over 60years: NTpro BNP range 60-16071 pg/ml; females over 56 years: N-MID-proANP range 83-280 pmol/l). Serum levels of NT-proBNP in patients were significantly elevated above the cut off values (100 pg/ml for males, 150 pg/ml for Evidence for natriuretic peptides A and B as non-invasive markers in congenital and valvular heart disease Reference values of both natriuretic peptides were calculated from the group of healthy blood donors and were previously published in 2, 16, 20 . Wilcoxon Signed rank test was used to test the statistical significance between medians of reference group and patients with congenital and valvular heart disease. Value of p <0.05 was considered as significant difference. S-significant, NS-non-significant females and 125 pg/ml for all patients) approved for the NT-proBNP assay. The blood serum and plasma levels of both natriuretic peptides correlate well with the measured cardiological parameters (diastolic blood pressure and systolic blood pressure, left ventricular ejection fraction (LVEF), history of acute myocardial infarction (AMI)).
DISCUSSION
The presented study shows the complex approach to investigation of valvular heart diseases with biochemical and cardiovascular surveillance of patients.
To date, several studies show the relevance of natriuretic peptides in valvular and congenital heart diseases. The present results confirm the findings of other studies showing significantly elevated levels of natriuretic peptides in various types of congenital and valvular heart diseases [3] [4] [5] . Other studies have shown a relationship between concentrations of natriuretic peptides and severity of heart failure [6] [7] [8] [9] [10] [11] [12] . In agreement with previous publications [6] [7] [8] [9] [10] [11] [12] , the levels of both natriuretic peptides increased with severity of the heart impairment. The highly significant relationship to age and gender for both natriuretic peptides found, accords with other studies [13] [14] [15] [16] [17] [18] . Diuretics, ACE inhibitors, angiotensin receptor antagonists, betablockers and renal impairment have been shown to decrease levels of natriuretic peptides 19 . In the present study, 27 of 82 patients were treated by drugs but only three of these patients showed significantly lower values of NTproBNP and NT-proANP. Nevertheless, these results correlated with increase of the left ventricular ejection fraction (over 60%) resulting in less severe heart impairment. Values of S-creatinine were investigated as a marker of renal impairment. In 80 of 82 patients, the results show normal levels of S-creatinine according to the age and gender. One patient had mildly elevated levels of S-creatinine (130 μmol/l) and one patient had significantly elevated level of S-creatinine (200 μmol/l). In both patients, the levels of natriuretic peptides were significantly higher than reference values (1 st patient: S-creatinine: 130 μmol/l, NT-proBNP -1040 pg/ml, N-MID-proANP 78 pg/ml; 2 nd patient: -S-creatinine: 200 μmol/l, NT-proBNP -16071 pg/ml, N-MID-proANP 504 pg/ml) In both cases, levels of natriuretic peptides correlated with the severity of heart impairment (LVEF = 35% and 10% respectively).
In conclusion, the results of the present study indicate that the natriuretic peptides (NT-proBNP and N-MIDproANP) are well appropriate as non-invasive cardiac biochemical markers in establishing diagnosis, as well as in management and treatment of valvular and congenital heart diseases.
